ICON to Create Translational Medicine Unit in UK

Monday, December 21, 2009 07:53 AM

Dublin-based contract research organization (CRO) ICON is preparing to open a new hospital-based translational medicine unit in the UK—the result of a partnership with the Central Manchester University Hospitals Foundation (CMFT).

Under the terms of the agreement, signed last summer, ICON will create translational medicine facilities on the newly developed Manchester Royal Infirmary (MRI) campus. The exclusive agreement, which runs until 2012, will help ICON meet increasing demand for hospital-based first-in-human studies.

The new unit—the first deliverable from the ICON-CMFT collaboration—will open in April, and will include 34 beds, an onsite Good Manufacturing Practices pharmacy, a sample handling laboratory and administrative space. It will be connected to MRI’s Accident and Emergency Department.  The unit will also offer environmentally controlled pharmacodynamic study testing suites.

ICON will develop an additional facility on the MRI campus.

The CRO would not comment on the size of its translational medicine business but said translational research is a growth area.

 

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs